Bioengineered Skin and Soft Tissue Substitute for Breast Reconstruction, Epidermolysis Bullosa Dystrophica (EBD), and Severe Burns
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - North Carolina policy alerts
Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.
Monitor payer policy activity
Medicare-focused coverage policy for use of bioengineered skin and soft tissue substitutes for breast reconstruction post-mastectomy, dystrophic epidermolysis bullosa, and second- or third-degree burns; applies to Blue Medicare products administered by Blue Cross NC and affects providers treating these members.
No material clinical or coverage changes in this revision.
Coverage Criteria
Medically necessary code pairing
Products may be medically necessary when ALL of the following are met:
Also applies to breast reconstruction following mastectomy where indicated; billing must include the appropriate skin substitute product; BCBSNC may request medical records.
All skin and soft tissue substitutes and their applications that are not explicitly listed in this policy are considered investigational and are not approved for coverage under this policy. Use of skin substitutes is not considered reasonable and necessary for wounds with signs of clinical infection, for wounds lacking adequate circulation to the affected area, or for wounds with exposed bone, tendon, or fascia. Patients with uncontrolled systemic factors that impede healing are excluded, including those with an HbA1c >12%. Additionally, skin substitutes are not approved for plan members with active Charcot arthropathy of the ulcer extremity when used for indications other than diabetic foot ulcers.
Letters of support or explanation may be helpful when medical records are requested, but they are not sufficient alone to establish medical necessity. Such letters must include all specific clinical information required for a medical necessity determination and be supported by the full medical record when requested by BCBSNC.
Per-episode application limits are enforced: more than four applications of a skin substitute or cellular therapy product within a single skin replacement episode (defined as 12 weeks from the first application) is considered not reasonable or necessary unless an exceptional-case review by the Plan Medical Director justifies additional applications. Application of a skin substitute beyond the 12-week episode window is similarly not routinely covered. Repeat applications following a prior unsuccessful application (defined by increased ulcer size or depth, no measurable change, or lack of signs of improvement) are not covered except in documented exceptional circumstances subject to review.
Billing for skin substitute application procedures must include reporting of the specific high-cost or low-cost skin substitute product in addition to the procedure code. Failure to report the appropriate product code or to provide required documentation when requested by BCBSNC may render the service not supportable for medical necessity review and could result in denial.
Coding and Code Lists
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast |
| Q81.2 | Dystrophic Epidermolysis Bullosa |
| T20 | Burn and corrosion of head, face, and neck |
| T21 | Burn and corrosion of trunk |
| T22 | Burn and corrosion of shoulder and upper limb, except wrist and hand |
| T23 | Burn and corrosion of wrist and hand |
| T24 | Burn and corrosion of lower limb, except ankle and foot |
| T25 | Burn and corrosion of ankle and foot |
| C50.011 | Malignant neoplasm of nipple and areola, right female breast |
| C50.012 | Malignant neoplasm of nipple and areola, left female breast |
| C50.019 | Malignant neoplasm of nipple and areola, unspecified female breast |
| C50.021 | Malignant neoplasm of nipple and areola, right male breast |
| C50.022 | Malignant neoplasm of nipple and areola, left male breast |
| C50.029 | Malignant neoplasm of nipple and areola, unspecified male breast |
| C50.111 | Malignant neoplasm of central portion of right female breast |
| C50.112 | Malignant neoplasm of central portion of left female breast |
| C50.119 | Malignant neoplasm of central portion of unspecified female breast |
| C50.121 | Malignant neoplasm of central portion of right male breast |
| Q4100 | EPICEL - Dermal or full thickness burns that cover 30% or more of the body surface area (BSA) |
Provider Actions, Documentation & Billing
Medical necessity and code reporting required
Coverage requires that the medical necessity criteria in this policy are met before payment; report the applicable HCPCS/Q-code for the skin or soft tissue substitute being used (examples listed include Q4100, Q4107, Q4116, Q4122, Q4128). Episodes that exceed four applications or extend beyond 12 weeks require Plan Medical Director review prior to continued authorization.
- Medical necessity criteria in Clinical Inclusion Criteria must be satisfied (product meets AATB standards or FDA approval; smoking status and wound characteristics documented).
- Applicable HCPCS/Q-code for the product must be reported with the procedure.
- Episodes with >4 applications or >12 weeks require Plan Medical Director review.
Report product (Group 1) with corresponding diagnosis (Group 2)
When billing, report a Group 1 CPT/HCPCS product code together with an appropriate Group 2 ICD-10-CM diagnosis code that corresponds to the clinical indication (e.g., Q4100, Q4104, Q4182 paired with T20–T25 for burns or Q81.2 for dystrophic EB).
- Group 1 product codes must be paired with Group 2 diagnosis codes for the indicated condition.
- For breast reconstruction, report the allogeneic ADM HCPCS/Q-code with the relevant breast malignancy ICD-10-CM code.
Episode limits: max 4 applications per 12-week episode
Limit applications to a maximum of four skin substitute applications per episode of skin replacement therapy (episode defined as 12 weeks from first application); additional applications or duration beyond 12 weeks require documentation of wound progression and Plan Medical Director review. Repeat applications after an unsuccessful prior application are not routinely covered.
- Episode = 12 weeks from first application; maximum 4 applications per episode.
- Additional applications or care beyond 12 weeks only with documentation of progression and Plan Medical Director review.
- Repeat applications after unsuccessful prior application (no improvement or recurrence within 12 months) are considered not reasonable or necessary.
Required clinical and coding documentation
Document smoking status (non-smoker or completed/ongoing cessation therapy), detailed wound characteristics and treatment plan (partial- or full-thickness defect; clean and free of necrotic debris/exudate/infection; tissue approximation concerns; no involvement of tendon/muscle/joint capsule/exposed bone), and that the product meets AATB standards or FDA approval. For breast reconstruction, include the applicable skin substitute HCPCS/Q-code with the breast cancer ICD-10-CM diagnosis code.
- Smoking status or smoking cessation therapy documented.
- Wound must be described as partial- or full-thickness, clean, and free of necrotic debris/exudate/infection; state why tissue approximation is not appropriate.
- Product regulatory status documented (AATB compliance or FDA approval).
- Report HCPCS/Q-code with corresponding ICD-10-CM diagnosis for breast reconstruction.
Make complete medical records available on request; letters alone are insufficient
Be prepared to provide medical records when requested by BCBSNC to support medical necessity determinations; letters of support are helpful but are not sufficient unless they contain all specific information needed for the medical necessity review.
- BCBSNC may request medical records to determine medical necessity.
- Letters of support alone are insufficient unless they include all specific required clinical information.
Avoid use on infected/ischemic/necrotic wounds or wounds with exposed structures
Do not apply skin substitutes to infected, ischemic, or necrotic wound beds, wounds with exposed bone/tendon/fascia, or in patients with uncontrolled factors such as HbA1c >12%; these uses are specifically listed as not approved and may result in denial.
- Use on wounds with clinical infection, inadequate circulation, exposed bone/tendon/fascia is not approved.
- HbA1c >12% is an exclusionary criterion.
- Placement on infected, ischemic, or necrotic wound bed is considered not reasonable or necessary and may be denied.
Link product code to application procedure and include required documentation
Ensure billing links the skin substitute product code with the skin substitute application procedure; failure to report the appropriate high-cost or low-cost product with the procedure code or lacking required documentation may make the service not supportable for medical necessity review.
- Billing for application procedures must include the appropriate high-cost or low-cost skin substitute product code.
- Lack of required documentation or failure to report the appropriate product code may result in denial.
Background
Bioengineered skin and soft tissue substitutes comprise a heterogeneous group of products used to cover or regenerate skin and soft tissue. These include acellular scaffolds—products processed to remove cellular components while preserving the collagen-rich extracellular matrix—and cellular products that contain living cells such as fibroblasts or keratinocytes (autologous, allogeneic, or xenogeneic). Products also vary by source (for example, amniotic membrane/allograft versus dermal matrix), processing (cryopreserved versus dehydrated), and intended duration of use; some are designed as temporary coverings and others for more durable integration. Typical clinical uses addressed by this policy include nonhealing wounds, surgical reconstruction (for example, postmastectomy breast reconstruction using acellular dermal matrices), management of dystrophic epidermolysis bullosa, and treatment of deep partial- or full-thickness burns.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.